BioCentury
ARTICLE | Company News

Sideris Pharmaceuticals, Novartis deal

October 28, 2013 7:00 AM UTC

Sideris granted Novartis an exclusive option to acquire Sideris in a deal that would value the company at up to $300 million, including upfront, acquisition and milestone payments. Sideris' SP-420 is...